{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007377","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.695662+00:00","generated_at":"2026-06-26T00:34:33.265380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track","bullets":["Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.","Cash, equivalents and investments $641.7M as of March 31, 2022.","FT596+R-CHOP clinical protocol for first-line aggressive lymphoma to be submitted to FDA in 2Q22.","FT536 CAR MICA/B NK cell product candidate on track for first patient treatment in 2Q22.","Third IND candidate nominated under Janssen collaboration triggering preclinical milestone payment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007377","json":"https://secwatch.observer/filing/0000950170-22-007377.json","markdown":"https://secwatch.observer/filing/0000950170-22-007377.md","text":"https://secwatch.observer/filing/0000950170-22-007377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/0000950170-22-007377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/fate-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:34:33.265380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}